D-0115-2021 Class III Terminated

Recalled by InvaTech Pharma Solutions, LLC — East Brunswick, NJ

FDA drug recall D-0115-2021 was initiated by InvaTech Pharma Solutions, LLC on Nov 11, 2020 and is designated Class III. Reason for recall: Failed Impurities/Degradation Specifications: One lot of Levocetirizine dihydrochloride tablets 5 mg 30 count failed stability testing. The recall status is terminated (terminated Jun 20, 2023).

Recall details

Product Type
Drugs
Report Date
Dec 9, 2020
Initiation Date
Nov 11, 2020
Termination Date
Jun 20, 2023
Voluntary/Mandated
Voluntary: Firm initiated

Product description

Levocetirizine Dihydrochloride Tablets, USP, 5 mg 30-count bottle, Rx Only, Distributed by: Marlex Pharmceuticals, Inc. New Castle, DE 19720. NDC 10135-0639-30

Reason for recall

Failed Impurities/Degradation Specifications: One lot of Levocetirizine dihydrochloride tablets 5 mg 30 count failed stability testing.

Distribution pattern

Distributed Nationwide in the USA

Code information

Lot #: 051944A Exp. Date April - 2021; 1119124 Exp Date Oct - 2021; 062088 Exp Date June - 2022;

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0115-2021
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0115-2021. Report a data issue: hello@regdatalab.com.